Page last updated: 2024-09-03

gefitinib and Cancer of Head

gefitinib has been researched along with Cancer of Head in 133 studies

Research

Studies (133)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's78 (58.65)29.6817
2010's48 (36.09)24.3611
2020's7 (5.26)2.80

Authors

AuthorsStudies
Liu, Y; Ma, Y; Wang, Y; Yao, C; Zhang, L1
Chen, BS; Lin, YC1
Cheng, SJ; Deng, YT; Ko, HH; Kuo, MY; Lee, HC; Lu, YJ; Peng, HH1
Antonio Casado, J; Arango, D; Bueren, JA; Carrascoso-Rubio, C; Carreras-Puigvert, J; González, A; Helleday, T; Lasa, A; Lerma, E; Martínez-Barriocanal, Á; Minguillón, J; Montanuy, H; Nieto, R; Ramírez, MJ; Riera, P; Rovirosa, L; Surrallés, J1
Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A1
Gong, X; Xiong, P; Zhou, L1
Argiris, A; Cella, D; Forastiere, AA; Lee, JW; Oswald, LB; Webster, KA1
Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD1
Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X1
Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X1
Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N1
Agarwal, V; Nayar, RC; Rao, V; Subash, A1
Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J1
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K1
Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C1
Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A1
He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y1
Adejumo, O; Allak, A; Hubbard, MA; Jameson, MJ; Khalil, AA; Maxwell, AK; Mendez, RE; Schoeff, SS; VanKoevering, KK1
Chiara, MD; de Santa-María, IS; Merlo, A; Secades, P; Suarez, C1
Benaich, N; Huang, Y; Kwok, HF; Murphy, G; Tape, C1
Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP1
Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H1
Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM1
Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S1
Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L1
Adamo, V; Caponigro, F; Franchin, G; Mari, E; Milano, A; Morrica, B; Pepe, S; Romano, C; Solla, R1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Sano, D; Taguchi, T; Toth, G; Tsukuda, M1
Agulnik, M; Wang, LX1
Agulnik, M; Brockstein, B; Lacouture, M1
Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H1
Abidoye, O; Salgia, R; Sattler, M1
Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F1
Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C1
Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL1
Barbachano, Y; Box, C; Chambers, P; Eccles, SA; Harrington, KJ; Nutting, CM; Rhŷs-Evans, P; Rogers, SJ; Workman, P1
Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S1
Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR1
Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE1
Allen, CT; Calvo, KR; Chen, Z; Dabir, B; Friedman, J; Morris, JC; Mundinger, GS; Pernas, FG; Saigal, K; Van Waes, C; Winters, ME; Xu, X; Yan, B1
Cohen, EE; Cooper, JB1
Chen, ZG; Ferris, RL; Grandis, JR; Ming, L; Sun, Q; Thomas, SM; Wang, Y; Yu, J; Zhang, L1
Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R1
Hata, R; Imagawa-Ishiguro, Y; Ito, S; Kato, Y; Komori, R; Kubota, E; Maehata, Y; Ozawa, S; Ozono, S; Shiiki, N; Taguchi, T; Tsukinoki, K; Tsukuda, M1
Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C1
Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M1
Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW1
Bozec, A; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Milano, G1
Acheson, KL; Beran, GJ; Bunn, PA; Cassidy, AM; French, T; Graham, A; Hickinson, DM; Hirsch, FR; Holloway, BR; Marshall, GB; McCormack, RM; McWalter, G; Mills, EA; South, MC; Speake, G; Varella-Garcia, M1
Amornphimoltham, P; Chiorini, JA; Gutkind, JS; Schmidt, M; Weller, ML; Wilson, PA1
Blair, EA; Brockstein, B; Cohen, EE; Dekker, A; Dignam, JJ; Grushko, TA; Haraf, DJ; Kunnavakkam, R; Lester, EP; Lingen, MW; Olopade, OI; Salama, JK; Stenson, KM; Vokes, EE; Williams, R; Witt, ME1
Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME1
Grazioso Russi, E; Numico, G; Silvestris, N1
Ferreira, CG; Herchenhorn, D1
Argyle, DJ; Bergkvist, GT; Muirhead, R; Pang, LY; Yool, DA1
Hopper, C; Jerjes, W; Mahil, J; Sudhoff, H; Upile, T1
Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H1
Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M1
Ang, MK; Baskaran, N; Goh, C; Hui, KM; Hwang, J; Khoo, ML; Lim, A; Lim, TH; Lim, WT; Ng, QS; Soo, KC; Tan, DS; Tan, EH; Tan, PH; Tan, SH; Tan, T; Teng, YH1
Chen, C; D'Cruz, AK; Fijuth, J; Gregoire, V; Hamoir, M; Julka, PK; Kane, M; Kawecki, A; Korzeniowski, S; Kumar, RR; Machiels, JP; Prasad, S; Raben, D; Radosevic-Jelic, L; Sellers, MV; Tchakov, I; Wang, HM1
Liebmann, C; Weisheit, S1
Adelstein, DJ; Ives, DI; Michal, SA; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG1
Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG1
Agulnik, M1
Chambers, MS; El-Naggar, AK; Feng, L; Glisson, BS; Lewis, CM; Lustig, RA; Rosenthal, DI; Tang, X; Wan, F; Weber, RS; Wistuba, II1
Fujii, M; Hasegawa, Y; Ijichi, K; Kondo, E; Maseki, S; Murakami, S; Nakanishi, H; Ogawa, T; Tanaka, H1
Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA1
Abhold, EL; Altuna, X; Blair, KJ; Brumund, KT; Haas, M; Kiang, A; Kuo, SZ; Lopez, JP; Ongkeko, WM; Patel, A; Rahimy, E; Wang-Rodriguez, J; Weisman, RA; Yu, MA1
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N1
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE1
Bensadoun, RJ; Bertucci, F; Cayre, A; Dassonville, O; De Raucourt, D; Etienne-Grimaldi, MC; Finetti, P; Geoffrois, L; Giraud, P; Grall, D; Milano, G; Morinière, S; Penault-Llorca, F; Racadot, S; Sudaka, A; Thariat, J; Van Obberghen-Schilling, E1
Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D1
Johansson, AC; La Fleur, L; Roberg, K1
Cohen, EE; Grushko, T; Liu, J; Liu, W; Olopade, OI; Pierce, C; Seiwert, TY; Shen, C; Wei, TF; Young, NR1
Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM1
Armstrong, EA; Harari, PM; Huang, SM; Li, J1
Ranson, M1
Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H1
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H1
Baselga, J; Hammond, LA1
Abbruzzese, A; Avallone, A; Barbarino, M; Bruzzese, F; Budillon, A; Caponigro, F; Caraglia, M; Comella, P; De Lorenzo, S; Di Gennaro, E; Pepe, S1
Lorusso, PM1
Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE1
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Magné, N; Milano, G; Renée, N; Tiffon, C1
Hamakawa, H; Kayahara, H; Kiyota, A; Mihara, M; Nakashiro, K; Shintani, S; Sumida, T1
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C1
Pérez-Soler, R1
Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z1
Ochs, JS1
Caponigro, F1
Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X1
Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL1
Von Pawel, J1
Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C1
Arnheim, K1
Al-Hazzaa, A; Birchall, MA; Bowen, ID; Randerson, P1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X1
Bell, DW; Brannigan, BW; Clark, JR; Cohen, EE; Dahiya, S; Haber, DA; Harris, PL; Haserlat, SM; Lingen, MW; Martin, LE; Muir, B; Okimoto, RA; Rocco, JW; Sgroi, DC; Vokes, EE1
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE1
Chai, RL; Grandis, JR1
Harari, PM; Huang, S1
Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM1
Arra, C; Avallone, A; Bruzzese, F; Budillon, A; Caraglia, M; Di Gennaro, E; Pepe, S; Tagliaferri, P1
A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M1
Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N1
Aguilera, J; Altuna, X; Chen, JS; Chu, TS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J; Weisman, RA1
Hennemann, B1
Khuri, FR; Saba, NF; Shin, DM1
Fish-Steagall, A; Searcy, P; Sipples, R1
Cohen, EE1
Bogeschdorfer, F; Gronau, S; Riechelmann, H1
Elenius, K; Erjala, K; Grenman, R; Junttila, TT; Kulmala, J; Mali, P; Pulkkinen, J; Savisalo, M; Sundvall, M; Zhang, N1
Bozec, A; Fischel, JL; Formento, P; Gugenheim, J; Hofman, P; Lassalle, S; Milano, G1
Erjala, K; Grénman, R; Kulmala, J; Raitanen, M1
Eckardt, A; Morgan, MA; Reuter, CW1
Frederick, B; Gustafson, DL; Merz, AL; Raben, D1
Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X1
Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D1
Bozec, A; Formento, P; Hofman, P; Lassalle, S; Lippens, C; Milano, G1
Gyergyay, F1
Tsukuda, M1
Daly, RJ; Lehrbach, GM; Musgrove, EA; Sutherland, RL; Timpson, P; Wilson, AS1
Elenius, K; Erjala, K; Grénman, R; Kulmala, J; Sundvall, M; Zhang, N1
Baron, A; Campana, J; Chen, C; Dancey, J; Eckhardt, SG; Harrison, L; Hu, K; Kane, M; Quon, H; Raben, A; Raben, D; Said, S; Song, J1
Imagawa-Ishiguro, Y; Kato, Y; Sano, D; Taguchi, T; Tsukuda, M1
Accardi, R; Azzariti, A; Conti, D; LaCalamita, R; Paradiso, A; Pilato, B; Porcelli, L; Sebastian, S; Simone, GM; Tommasi, S; Tommasino, M1
Albanell, J; Anido, J; Baselga, J; Codony-Servat, J; Del Campo, JM; Giralt, J; Mendelsohn, J; Nicholson, RI; Raspall, G; Rojo, F; Roselló, J; Sauleda, S1
Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G1
Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D1
Dubreuil, A; Fischel, JL; Formento, P; Laurent-Puig, P; Magné, N; Milano, G; Poupon, MF1

Reviews

26 review(s) available for gefitinib and Cancer of Head

ArticleYear
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
    Respiratory medicine, 2013, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors

2013
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines

2008
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
    TheScientificWorldJournal, 2008, Sep-21, Volume: 8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines

2008
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
    Head & neck, 2009, Volume: 31, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome

2009
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
    Head & neck, 2010, Volume: 32, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines

2010
Advances in EGFR-directed therapy in head and neck cancer.
    Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis

2011
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck

2012
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles

2012
ZD1839 (Iressa): for more than just non-small cell lung cancer.
    The oncologist, 2002, Volume: 7 Suppl 4

    Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome

2002
HER-targeted tyrosine-kinase inhibitors.
    Oncology, 2002, Volume: 63 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2

2002
Phase I studies of ZD1839 in patients with common solid tumors.
    Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2003
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:11 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome

2003
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
    International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents

2004
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
    Anti-cancer drugs, 2004, Volume: 15, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines

2004
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Bulletin du cancer, 2004, May-01, Volume: 91, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines

2004
Advances in molecular diagnostics and therapeutics in head and neck cancer.
    Current treatment options in oncology, 2006, Volume: 7, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; Diagnosis, Differential; DNA Methylation; DNA, Mitochondrial; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microsatellite Repeats; Prognosis; Quinazolines; RNA, Messenger

2006
Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
    Seminars in radiation oncology, 2006, Volume: 16, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2006
[Palliative chemotherapy of head and neck cancer: present status and future development].
    Laryngo- rhino- otologie, 2006, Volume: 85, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine

2006
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2006
Clinical experience with anti-EGFR therapy.
    Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome

2006
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome

2006
[New substances in the therapy of head and neck cancer].
    Laryngo- rhino- otologie, 2006, Volume: 85, Issue:7

    Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration

2006
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
    British journal of cancer, 2007, Feb-12, Volume: 96, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2007
[Head and neck: molecular-targeted therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines

2007
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 4

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Chemoprevention; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Up-Regulation

2002

Trials

25 trial(s) available for gefitinib and Cancer of Head

ArticleYear
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302).
    Cancer medicine, 2020, Volume: 9, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Predictive Value of Tests; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Symptom Assessment; Treatment Outcome

2020
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome

2013
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
    Onkologie, 2013, Volume: 36, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome

2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays

2013
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
    Cancer biology & therapy, 2015, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2015
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2008, Volume: 19, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Quinazolines; Radiotherapy Dosage

2008
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
    American journal of clinical oncology, 2008, Volume: 31, Issue:6

    Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis

2008
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
    Cancer, 2009, May-15, Volume: 115, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome

2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome

2009
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Oral oncology, 2009, Volume: 45, Issue:10

    Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome

2009
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis

2010
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines

2010
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Matrix Metalloproteinase 11; Middle Aged; Oligonucleotide Array Sequence Analysis; Quinazolines; Risk Factors; Smoking; Treatment Outcome

2012
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 100, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Double-Blind Method; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Squamous Cell Carcinoma of Head and Neck

2011
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
    Head & neck, 2012, Volume: 34, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult

2012
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Skin Neoplasms; Survival Analysis; Treatment Outcome

2012
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral oncology, 2012, Volume: 48, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin

2012
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Treatment Outcome

2012
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases

2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome

2002
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome

2003
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides

2005
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A

2005
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer.
    British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis

2006
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines

2007

Other Studies

82 other study(ies) available for gefitinib and Cancer of Head

ArticleYear
Epithelial Membrane Protein 1 Promotes Sensitivity to RSL3-Induced Ferroptosis and Intensifies Gefitinib Resistance in Head and Neck Cancer.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Cell Line, Tumor; Ferroptosis; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Receptors, Cell Surface; Squamous Cell Carcinoma of Head and Neck

2022
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
    International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18

    Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Metformin; Mouth Neoplasms; NF-kappa B; Squamous Cell Carcinoma of Head and Neck; Systems Biology

2022
Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.
    Cancer science, 2023, Volume: 114, Issue:10

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mouth Neoplasms; Protein-Lysine 6-Oxidase; RNA-Binding Proteins; Squamous Cell Carcinoma of Head and Neck

2023
Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12

    Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Fanconi Anemia; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck

2020
[Gefitinib/chloroquine-liposome-microbubble complexes as ultrasound-triggered therapeutic particles for head and neck squamous cell carcinoma in vitro].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2020, Volume: 29, Issue:2

    Topics: Cell Line, Tumor; Chloroquine; Gefitinib; Head and Neck Neoplasms; Humans; Liposomes; Microbubbles; Squamous Cell Carcinoma of Head and Neck

2020
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
    Anticancer research, 2017, Volume: 37, Issue:6

    Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines

2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
    Nature communications, 2017, 09-05, Volume: 8, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins

2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
    Nature medicine, 2017, Volume: 23, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2017
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Oncology reports, 2018, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2018
Is EGFR really a therapeutic target in head and neck cancers?
    Journal of surgical oncology, 2019, Volume: 119, Issue:6

    Topics: Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Radiotherapy, Adjuvant

2019
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Molecular pharmacology, 2019, Volume: 95, Issue:5

    Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides

2019
Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014, Volume: 151, Issue:1

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Feasibility Studies; Gefitinib; Head and Neck Neoplasms; Heterografts; Immunoassay; In Vitro Techniques; Mice; Nanotechnology; Quinazolines

2014
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth fact
    Head & neck, 2015, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; In Vitro Techniques; Membrane Proteins; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins; Quinazolines; Sensitivity and Specificity; Signal Transduction; Vascular Endothelial Growth Factor A

2015
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
    International journal of biological sciences, 2014, Volume: 10, Issue:7

    Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Antibodies; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Quinazolines; Signal Transduction

2014
ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Anoctamin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chloride Channels; ErbB Receptors; Fusion Regulatory Protein 1, Heavy Chain; Gefitinib; Head and Neck Neoplasms; HEK293 Cells; Humans; Multiprotein Complexes; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Squamous Cell Carcinoma of Head and Neck

2015
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck

2016
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Cancer letters, 2016, 10-10, Volume: 381, Issue:1

    Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection

2016
Gefitinib enhances radiotherapeutic effects of
    Nuclear medicine and biology, 2017, Volume: 48

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution

2017
Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
    Oncology reports, 2008, Volume: 20, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured

2008
Promising newer molecular-targeted therapies in head and neck cancer.
    Drugs, 2008, Volume: 68, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21

    Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines

2008
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-01, Volume: 15, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured

2009
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
    The Journal of pathology, 2009, Volume: 218, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Genes, erbB-2; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Linear Models; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Quinazolines

2009
A case report of thyroid cancer showing a remarkable effect of gefitinib.
    Auris, nasus, larynx, 2009, Volume: 36, Issue:5

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2009
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; NF-kappa B; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction

2009
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Oncogene, 2009, Jun-18, Volume: 28, Issue:24

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2009
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
    Cancer science, 2009, Volume: 100, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemokines, CXC; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mutation; Quinazolines; RNA, Messenger

2009
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays

2010
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.
    Oral oncology, 2010, Volume: 46, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous

2010
Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
    Clinical and translational science, 2009, Volume: 2, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gefitinib; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Quinazolines; RNA, Messenger

2009
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.
    Nature medicine, 2010, Volume: 16, Issue:6

    Topics: Animals; Cell Line, Tumor; Dependovirus; ErbB Receptors; Female; Gefitinib; Gene Expression; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Isoantigens; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptors, Virus; Transduction, Genetic; Tyrphostins

2010
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-01, Volume: 29, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiotherapy, Adjuvant; Treatment Outcome

2011
Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors.
    Cancer biology & therapy, 2011, Jun-01, Volume: 11, Issue:11

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cats; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Conserved Sequence; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance; RNA Interference; Signal Transduction

2011
The use of optical technology to monitor the antiangiogenic effects of gefitinib treatment for advanced head and neck squamous cell carcinoma: a brief report.
    Lasers in medical science, 2012, Volume: 27, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Endoscopy; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Optics and Photonics; Quinazolines

2012
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays

2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Journal of cellular physiology, 2011, Volume: 226, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat

2011
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
    Cellular signalling, 2012, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection

2012
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
    Head & neck, 2012, Volume: 34, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enteral Nutrition; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Neutropenia; Quinazolines; Radiotherapy Dosage; Registries; Retrospective Studies

2012
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors

2012
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.
    Veterinary journal (London, England : 1997), 2012, Volume: 193, Issue:1

    Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck

2012
EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplasm Invasiveness; Neoplastic Stem Cells; Quinazolines; Signal Transduction

2012
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    International journal of cancer, 2013, Mar-01, Volume: 132, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck

2013
A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Cell Shape; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Flow Cytometry; Gamma Rays; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Organ Specificity; Quinazolines

2012
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Molecular oncology, 2013, Volume: 7, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mutation; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck

2013
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    BMC cancer, 2013, Jan-18, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies

2013
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Cancer research, 2002, Aug-01, Volume: 62, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Endothelium, Vascular; ErbB Receptors; Female; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2002
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Journal of cellular physiology, 2003, Volume: 195, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Macromolecular Substances; Oligonucleotides, Antisense; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins

2003
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    British journal of cancer, 2003, Aug-04, Volume: 89, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cisplatin; DNA Repair; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2003
Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    American journal of clinical oncology, 2003, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance

2003
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic

2003
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin

2004
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Cancer research, 2004, Aug-01, Volume: 64, Issue:15

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured

2004
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

    Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins

2004
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors

2004
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
    Cancer research, 2004, Dec-15, Volume: 64, Issue:24

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin

2004
[Successes in late solid tumors. New therapy offer].
    MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Quinazolines; Salvage Therapy; Time Factors

2004
The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
    Cell proliferation, 2005, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Suppressor Protein p53

2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides

2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2005
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-15, Volume: 11, Issue:22

    Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome

2005
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
    Cancer research, 2006, Jan-15, Volume: 66, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured

2006
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2006
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
    Cancer research, 2006, Mar-15, Volume: 66, Issue:6

    Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A

2006
EGFR regulates the side population in head and neck squamous cell carcinoma.
    The Laryngoscope, 2006, Volume: 116, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Vitro Techniques; Neoplasm Proteins; Quinazolines

2006
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Structure-Activity Relationship; Time Factors

2006
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
    British journal of cancer, 2006, Sep-18, Volume: 95, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Organophosphorus Compounds; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays

2006
Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:3

    Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2007
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2008
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Rats; Transplantation, Heterologous

2007
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids

2007
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines

2007
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.
    British journal of cancer, 2007, Jul-02, Volume: 97, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2007
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Magyar onkologia, 2007, Volume: 51, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant

2007
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
    Cancer research, 2007, Oct-01, Volume: 67, Issue:19

    Topics: Anoikis; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Growth Processes; Chromosomes, Human, Pair 11; Cortactin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction

2007
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2007, Volume: 85, Issue:1

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Receptor, ErbB-3; Vinblastine; Vinorelbine

2007
Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
    Oncology reports, 2008, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2008
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.
    International journal of molecular medicine, 2008, Volume: 21, Issue:6

    Topics: Acid Anhydride Hydrolases; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; DNA-Binding Proteins; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Membrane Proteins; Mutation; Neoplasm Proteins; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2008
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Cancer research, 2001, Sep-01, Volume: 61, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction; Skin; Transforming Growth Factor beta

2001
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
    British journal of cancer, 2002, Mar-04, Volume: 86, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gefitinib; Genes, p53; Head and Neck Neoplasms; Humans; Quinazolines; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured

2002
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    British journal of cancer, 2002, May-06, Volume: 86, Issue:9

    Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2002